Nalaganje...
Impact of empagliflozin on diabetic kidney disease
Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule‐glomerular feedback, thereby protect against diabetes‐induced caidio‐renal injuries.[Image: see text]
Shranjeno v:
| izdano v: | J Diabetes Investig |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5583951/ https://ncbi.nlm.nih.gov/pubmed/28035769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12615 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|